Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland
December 27, 2022 13:04 ET
|
AB Science
PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext - FR0010557264...
Infant Bacterial Therapeutics AB (publ) (IBT), delårsrapport 1 juli – 30 september 2022
November 10, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och som jag tidigare nämnt arbetar vi med flera aktiviteter för att påskynda genomförandet av vår studie. Det är...
Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022
November 10, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development project is progressing well, and as previously mentioned, we are pursuing several initiatives to accelerate study execution. It is...
Artikel baserad på Infant Bacterial Therapeutics “Connection Study” publicerad i British Journal of Gastroenterology visar att en dags minskning av tiden till “Sustained Feeding Tolerance (SFT)” korrelerar med klinisk meningsfulla resultat
November 01, 2022 03:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) "Connection Study" består av två oberoende primära endpoints, förekomsten av NEC och tiden tills man når SFT. SFT ett sammansatt effektmått definierat som den...
Article based on Infant Bacterial Therapeutics’ (IBT) Connection Study published in the British Journal of Gastroenterology demonstrates that one day shift in Sustained Feeding Tolerance (SFT) correlates to clinically meaningful outcomes.
November 01, 2022 03:00 ET
|
Infant Bacterial Therapeutics AB
The two independent primary endpoints of the ‘Connection Study’ are the incidence of NEC and the time to SFT. SFT a composite endpoint defined as the first day of tolerating daily enteral feeds of...
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
October 25, 2022 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
FDA godkänner Infant Bacterial Therapeutics “orphan drug” ansökan
September 23, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Med Infant Bacterial Therapeutics AB:s (IBT) unika kompetens inom utveckling av nya behandlingar till för tidigt födda barn är IBT i ett tidigt skede av en undersökning som syftar till utreda...
FDA approves Infant Bacterial Therapeutics' request for a new orphan drug designation
September 23, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Building upon Infant Bacterial Therapeutics AB’s (IBT) unique expertise in developing treatment solutions for preterm infants, IBT is at an early stage of investigating the possibilities of developing...
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
August 30, 2022 10:37 ET
|
Trethera Corporation
LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement January 1-June 30, 2022
August 25, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development program is progressing well. We have seen an overall acceleration of recruitment rates and, as mentioned previously, have been...